Navigation Links
Because of Its Ability to Generate Higher Total Sales in the United States and Europe, Lucentis Will Earn Clinical Gold Standard Status by 2011 for the Treatment of Diabetic Retinopathy
Date:6/26/2008

A Drug with Superior Efficacy to Avastin at Improving Visual Acuity When Used with Laser Photocoagulation Would Earn a 20 Percent Patient Share,

According to a New Report from Decision Resources

WALTHAM, Mass., June 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Genentech/Novartis's Lucentis will become the Decision Resources' proprietary clinical gold standard by 2011 because of its ability to generate higher total sales in the United States and Europe due to its higher price. Although ophthalmologists perceive Lucentis as offering comparable efficacy to the current clinical gold standard, Avastin, Lucentis exhibits slightly greater affinity than Avastin to vascular endothelial growth factor (VEGF). If data continue to be positive for Avastin however, it will likely maintain a strong patient-share advantage over Lucentis and others because of its lower price.

The new report entitled Diabetic Retinopathy: Future Demand to Be Driven by Agents that Improve Visual Acuity also finds that a therapy that is more effective than Avastin at improving visual acuity when used in conjunction with laser photocoagulation therapy, would earn a 20 percent patient share in the treatment of diabetic retinopathy. Surveyed ophthalmologists indicate that an improvement -- not maintenance -- in visual acuity is fast becoming the target outcome of treatment for diabetic retinopathy including for patients with diabetic macular edema.

"Ophthalmologists we surveyed indicated that they would prescribe agents that fulfill either the Minimal Acceptable or Major Achievement profiles to 20 percent of their diabetic retinopathy patients," said Caroline Gates, B.Sc., analyst at Decision Resources. "Given the price set for each of the target product profiles and the forecasted size of the diabetic retinopathy patient population in 2011, a 20 percent patient share would result in sales of $42.7 million for an agent fitting the Minimal Acceptable drug profile and $320.3 million for an agent fitting the Major Achievement profile."

About the Report

Diabetic Retinopathy: Future Demand to Be Driven by Agents that Improve Visual Acuity is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be

trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Emergency responders at high risk to miss work because of injuries
2. The American Red Cross Releases Book Devoted to Your Dogs Health - Because Your Dog is Counting on You
3. 13 percent of women stop taking breast cancer drug because of side effects, U-M study finds
4. GoAmerica(R) and AT&T to Demonstrate Fast, Effective 10-Digit Interoperability Between Video Relay Providers
5. Concuity Announces the Availability of PriceAdvisor
6. Launch of help2getbetter.com Provides Convenience and Portability to Household Medicines
7. Regence Pilot Shows Affordability of Electronic Medical Records
8. Baxter Releases Ninth Annual Sustainability Report
9. Human Factors International Sponsors Usability Professionals Association (UPA) 2008 International Conference
10. Ability to track stem cells in tumors could advance cancer treatments
11. Therap Services Announces Release 7.3 for the Developmental Disability Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
Breaking Medicine Technology: